Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
2007-003624-37Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dasatinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoint - long-term safety. Started Aug 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2007-003624-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003624-37.